Sex-based differences in the effect of digoxin for the treatment of heart failure

New England Journal of Medicine

Volumn 347, Issue 18, 2002, Pages 1403-1411

  Rathore, Saif S ^a   Wang, Yongfei ^b   Krumholz, Harlan M ^c  

^a Section of Cardiovascular Medicine   (United States)

^b Section of Health Policy and Administration   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIGOXIN; PLACEBO;

ADULT; AGED; ARTICLE; CAUSE OF DEATH; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFECT; FEMALE; HEART FAILURE; HEART LEFT VENTRICLE CONTRACTION; HOSPITALIZATION; HUMAN; MALE; MORTALITY; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SEX DIFFERENCE;

AGED; CARDIOTONIC AGENTS; CARDIOVASCULAR DISEASES; DIGOXIN; FEMALE; HEART FAILURE, CONGESTIVE; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODELS; RANDOMIZED CONTROLLED TRIALS; RISK FACTORS; SEX FACTORS; SURVIVAL ANALYSIS; VENTRICULAR DYSFUNCTION, LEFT;

EID: 0037206368     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMoa021266     Document Type: Article

References (42)

1. The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997;336:525-33.
2. Hunt SA, Baker DW, Chin MH, et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: Executive summary: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure). Circulation 2001;104:2996-3007
3. Remme WJ, Swedberg K. Guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J 2001;22:1527-60.
4. Heart Failure Society of America (HFSA) practice guidelines: HFSA guidelines for management of patients with heart failure caused by left ventricular systolic dysfunction - Pharmacological approaches. J Card Fail 1999;5:357-82.
5. Wenger NK. Women, heart failure, and heart failure therapies. Circulation 2002;105:1526-8.
6. 2002 Heart and Stroke Statistical Update. Dallas: American Heart Association, 2001.
7. Croft JB, Giles WH, Pollard PA, Keenan NL, Casper ML, Anda RF. Heart failure survival among older adults in the United States a poor prognosis for an emerging epidemic in the Medicare population. Arch Intern Med 1999;159:505-10.
8. Ho KK, Anderson KM, Kannel WB, Grossman W, Levy D. Survival after the onset of congestive heart failure in Framingham Heart Study subjects. Circulation 1993;88:107-15.
9. Schocken DD, Arrieta MI, Leaverton PE, Ross EA. Prevalence and mortality rate of congestive heart failure in the United States J Am Coll Cardiol 1992;20:301-6.
10. Adams KF Jr, Dunlap SH, Sueta CA, et al. Relation between gender, etiology and survival in patients with symptomatic heart failure. J Am Coll Cardiol 1996;28:1781-8.
11. Lindenfeld J, Krause-Steinrauf H, Salerno J. Where are all the women with heart failure? J Am Coll Cardiol 1997;30:1417-9.
12. Levy D, Larson MG, Vasan RS, Kannel WB, Ho KK. The progression from hypertension to congestive heart failure. JAMA 1996;275:1557-62.
13. Ho KK, Pinsky JL, Kannel WB, Levy D. The epidemiology of heart failure: The Framingham Study. J Am Coll Cardiol 1993;22:Suppl 4:6A-13A.
14. Aronson D, Burger AJ. Gender-related differences in modulation of heart rate in patients with congestive heart failure. J Cardiovasc Electrophysiol 2000;11:1071-7.
15. Dash R, Frank KF, Carr AN, Moravec CS, Kranias EG. Gender influences on sarcoplasmic reticulum Ca2+-handling in failing human myocardium. J Mol Cell Cardiol 2001;33:1345-53.
16. Griffin M, Lee HW, Zhao L, Eghbali-Webb M. Gender-related differences in proliferative response of cardiac fibroblasts to hypoxia: Effects of estrogen. Mol Cell Biochem 2000;215:21-30.
17. Kadokami T, McTiernan CF, Kubota T, Frye CS, Feldman AM. Sex-related survival differences in murine cardiomyopathy are associated with differences in TNF-receptor expression. J Clin Invest 2000;106:589-9Z
18. Riemer RK, Wu YY, Bottari SP, Jacobs MM, Goldfien A, Roberts JM. Estrogen reduces beta-adrenoceptor-mediated cAMP production and the concentration of the guanyl nucleotide-regulatory protein, Cs, in rabbit myometrium. Mol Pharmacol 1988;33:389-95.
19. Song M, Helguera G, Eghbali M, et al. Remodeling of Kv4.3 potassium channel gene expression under the control of sex hormones. J Biol Chem 2001;276:31883-90.
20. Schaible TF, Malhotra A, Ciambrone G, Scheuer J, The effects of gonadectomy on left ventricular function and cardiac contractile proteins in male and female rats. Circ Res 1984;54:38-49.
21. Duscha BD, Annex BH, Keteyian SJ, et al. Differences in skeletal muscle between men and women with chronic heart failure. J Appl. Physiol 2001;90:280-6.
22. Tamura T, Said S, Gerdes AM. Gender-related differences in myocyte remodeling in progression to heart failure. Hypertension 1999;33:676-80.
23. Carroll JD, Carroll EP, Feldman T, et al. Sex-associated differences in left ventricular function in aortic stenosis of the elderly. Circulation 1992;86:1099-107.
24. Rationale, design, implementation, and baseline characteristics of patients in the DIG trial: A large, simple, long-term trial to evaluate the effect of digitalis on mortality in heart failure. Control Clin Trials 1996;7:77-97.
25. Jelliffe RW, Brooker G. A nomogram for digoxin therapy. Am J Med 1974;57:63-8.
26. Pocock SJ, Hughes MD. Estimation issues in clinical trials and overviews. Stat Med 1990;9:657-71.
27. Matthews JNS, Altman DG. Interaction 3: How to examine heterogeneity. BMJ 1996;313:862.
28. Brookes ST, Whitley E, Peters TJ, Mulheran PA, Egger M, Davey Smith G. Subgroup analyses in randomised controlled trials: Quantifying the risks of false-positives and false-negatives. Health Technol Assess 2001;5:1-56.
29. Oxman AD, Guyatt GH. A consumer's guide to subgroup analyses. Ann Intern Med 1992;116:78-84.
30. Pocock SJ, Hughes MD, Lee RJ. Statistical problems in the reporting of clinical trials: A survey of three medical journals. N Engl J Med 1987;317:426-32.
31. Assmann SF, Pocock SJ, Enos LE, Kasten LE. Subgroup analysis and other (mis)uses of baseline data in clinical trials. Lancet 2000;355:1064-9.
32. Yusuf S, Wittes J, Probstfield J, Tyroler HA. Analysis and interpretation of treatment effects in subgroups of patients in randomized clinical trials. JAMA 1991;266:93-8.
33. Freemantle N. Interpreting the results of secondary end points and subgroup analyses in clinical trials: Should we lock the crazy aunt in the attic? BMJ 2001;322:989-91.
34. Buyse ME. Analysis of clinical trial outcomes: Some comments on subgroup analyses. Control Clin Trials 1989;10:Suppl:187S-194S.
35. Simon R. Patient subsets and variation in therapeutic efficacy. Br J Clin Pharmacol 1982;14:473-82.
36. Moye LA. Random research. Circulation 2001;103:3150-3.
37. Petrie MC, Dawson NF, Murdoch DR, Davie AP, McMurray JJ. Failure of women's hearts. Circulation 1999;99:2334-41.
38. Rich MW, McSherry F, Williford WO, Yusuf S. Effect of age on mortality, hospitalizations and response to digoxin in patients with heart failure: The DIG study. J Am Coll Cardiol 2001;38:806-13.
39. Aebi S, Schnider TW, Los G, et al. A phase II/pharmacokinetic trial of high-dose progesterone in combination with paclitaxel. Cancer Chemother Pharmacol 1999;44:259-65.
40. Furberg CD, Vittinghoff E, Davidson M, et. al. Subgroup interactions in the Heart and Estrogen/Progestin Replacement Study: Lessons learned. Circulation 2002;105:917-22.
41. Wizemann TM, Pardue M-L, eds. Exploring the Biological Contributions to Human Health: Does Sex Matter? Washington, D.C.: National Academy Press, 2001.
42. Heiat A, Gross CP, Krumholz HM. Representation of the elderly, women, and minorities in heart failure clinical trials. Arch Intern Med 2002;162:1682-8.